anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Please read this leaflet carefully before you take ZOMIG Tablets. This provides a summary of the information available on your medicine. Please do not throw away this leaflet until you have finished your medicine. You may need to read this leaflet again. This leaflet does not contain all the information on ZOMIG Tablets. For further information or advice, ask your doctor or pharmacist.
A new therapeutic approach for the destruction of cancerous cells by means of differentiation. This is based on the use of a model system (the egg cell in its broadest sense) and on the identification of an original biological target in cancer cells (immature mitochondria) and of molecules of therapeutic interest acting on the differentiation of this target. A new therapeutic approach for the destruction of cancer cells by differentiation. This is based on the claim that the understanding of cancer is a projection of fundamental medical research which produces new knowledge about the disease and its control. Independent claims are also included for (1) the use of a model system, that of the egg cell in the broadest sense: (a) the genesis of the egg cell and the triggering of its genetic programme as the closest model for the pathology, and (b) the perinatal period, for the identification of candidate drugs (2) the identification of an original biological target in the cancer cells, i.e. immature mitochondria, and of active molecules of therapeutic interest which can affect the differentiation of this target.
The invention discloses medicated wine for preventing and treating lumbar disc herniation. Adopted raw materials and parts by weight are respectively as follows: 35g of kadsura root-bark, 35g of pubescent angelica root, 20g of eucommia bark, 20g of suberect spatholobus stem, 10g of radix aconiti, 10g of kusnezoff monkshood, 15g of gynura segetum(Lour.)Merr, 6g of camphor and 6g of borneol. The preparation method of the medicated wine for preventing and treating the lumbar disc herniation comprises the following steps of: preparing the raw materials into decoction pieces, soaking in 2000 to 3000ml of white spirit of 38 to 52 degrees, filtering after sealing for 7 days, removing decoction dregs and packaging so as to prepare the medicated wine for preventing and treating the lumbar disc herniation. The drinking method is as follows: 5 to 8ml of medicated wine for preventing and treating the lumbar disc herniation is taken each time, and the medicated wine for preventing and treating the lumbar disc herniation is directly drunk. The medicated wine for preventing and treating the lumbar disc herniation has the effects of promoting the blood circulation, restoring the menstrual flow, expelling wind, removing dampness, warming channels to remove coldness and alleviating pains and has an obvious effect for preventing and treating the lumbar disc herniation.
PURPOSE:To provide a suppository having high rate of drug release, by adding a specific amount of a fatty acid alkali metal salt to a suppository containing an acidic drug. CONSTITUTION:A suppository containing an acidic drug (e.g. glycyrrhezic acid, indomethacin, ibuprofen, etc.) is added with >=0.01wt% and <0.5wt%, preferably 0.01-0.2wt% fatty acid alkali metal salt. The fatty acid is preferably 10-16C saturated fatty acid and the alkali metal salt is preferably Na salt or K salt. The additive is effective to increase the releasability of the acidic drug in the suppository from the base and improve the absorption and bioavailability of the drug.
The Type 2 Diabetic Treatment Group will be randomized to receive test material (2.0g SRT2104 or placebo) in the form of 8 capsules per day for 28 days. After 28 days of dosing, subjects will cross over to receive placebo or 2.0g SRT2104 for an additional 28 days. Dosing of SRT2104 or placebo will take place at approximately the same time every morning, approximately 15 minutes following consumption of a standardized morning meal (220 cc of Ensure Plus®). Subjects must wait at least 1-2 hours after dosing before consuming additional calories. Water is permitted ad libitum.
A young man from Pakistan had his first-ever tonic-clonic seizure while playing cricket. Since age 12 years, he had reported involuntary jerks and tremulousness, sometimes with falls, particularly with bright lights. Family history included a brother who developed seizures with myoclonus in his mid-20s and parental consanguinity. Developmental history was normal. Examination identified cognitive impairment with action myoclonus. His clinical presentation raised suspicion of a progressive myoclonus epilepsy. MR scan of the brain showed white matter changes suggesting leucodystrophy with cortical atrophy. Electroencephalogram showed generalised epileptiform abnormalities with photoparoxysmal responses, including at low frequencies (1 Hz). Cortical hyperexcitability was confirmed with giant median somatosensory evoked potentials and long loop reflexes at rest. Multichannel electromyography showed action myoclonus with variable synchronous and asynchronous agonist and antagonist muscle activation with short-burst duration of 25-75 ms, and jerk-locked back-averaging showed premyoclonic potentials consistent with cortical myoclonus. Genetic sequencing identified a homozygous missense variant in the CLN6 gene (c.768C>G p.(Asp256Glu), confirming Kufs disease type A.
The invention relates to a method for preparing a medicament for treating Heart cerebrovascular diseases. In the method, the following pure Chinese medicinal herbs are used as raw materials: leech, centipede, scorpion, earthworm, noded pit viper, wall lizard, gadfly, mole cricket, processed tuber of multiflower knotweed, hawthorn, oriental waterplantain rhizome, cassia occidentalis, root of pseudo-ginseng and nux vomica. Capsules are prepared by the steps of washing, impurities removal, slicing, air-drying, soaking, steaming and boiling, slow-fire frying, grinding, sieving and mixing. In a prescription disclosed by the invention, insect medicaments and nux vomica are used importantly and usually so as to rapidly and strongly break blood and remove blood stasis and eliminate stagnation and activate meridians. The medicament can make new and old thrombi rapidly dissolved, softens blood vessels, improves micro circulation, keeps and repairs damaged nerve cells, can make vitality of a patient recovered and release pain so as to further achieve the rehabilitation effect, has no side effects or adverse reaction and has wide and easily obtained drug resources and low cost. By years of clinical application, the effective rate of the medicament reaches 99.8 percent and the cure rate of the medicament reaches 75 percent.
The positive effects of female sex hormones, particularly estradiol and progesterone, have been observed in treatment of various pathologies. Acute kidney injury (AKI) is a common condition in hospitalized patients in which the molecular mechanisms of hormone action are poorly characterized. In this study, we investigated the influence of estradiol and progesterone on renal cells during ischemic injury. We performed both in vivo experiments on female and male rats and in vitro experiments on renal tubular cells (RTCs) obtained from the kidneys of intact animals of different sexes. Since mitochondria play an important role in the pathogenesis of AKI, we analyzed the properties of individual mitochondria in renal cells, including the area, roundness, mitochondrial membrane potential, and mitochondrial permeability transition pore (mPTP) opening time. We found that pre-treatment with progesterone or estradiol attenuated the severity of ischemia/reperfusion (I/R)-induced AKI in female rats, whereas in male rats, these hormones exacerbated renal dysfunction. We demonstrated that the mPTP opening time was higher in RTCs from female rats than that in those from male rats, which may be one of the reasons for the higher tolerance of females to ischemic injury. In RTCs from the kidneys of male rats, progesterone caused mitochondrial fragmentation, which can be associated with reduced cell viability. Thus, therapy with progesterone or estradiol displays quite different effects depending on sex, and could be only effective against ischemic AKI in females.
This is a Phase Ib, double-blind (neither physician nor patient knows the treatment that the patient receives), randomized (the study drug is assigned by chance), placebo-controlled study in treatment-naïve (someone who has never used drugs for HCV infection), Caucasian genotype 1 chronic HCV-infected patients. The study consists of a screening period, a 9-day treatment period (with 5 days of actual medication intake) and a 4-week follow-up period. The patients will be divided over 4 panels of 10 patients each that will be initiated sequentially. In each panel patients will receive JNJ-47910382 or placebo during 5 consecutive days. JNJ-47910382 or placebo will be administered once daily or twice daily. Within each panel, 5 patients of genotype-1a and 5 patients of genotype-1b will be enrolled. Patients will be randomly assigned to receive active treatment or placebo in such a way that 4 patients of each genotype receive active treatment and 1 subject of each genotype receives placebo. The pharmacokinetic profile of JNJ-47910382 will be assessed in each panel. HCV RNA kinetics (HCV RNA level) and HCV resistance will be studied and biomarkers at the messenger RNA (mRNA), protein and cell level will be explored. The entire study duration for each participant will be approximately four weeks.
PURPOSE:To obtain the titled complex, by reacting immunoglobulin having introduced functional groups reactive with thiol group with a thiol group- containing cytotoxic substance and treating the unreacted functional groups reactive with the thiol group with a thiol group-containing low-molecular compound. CONSTITUTION:Immunoglobulin having introduced functional groups reactive with thiol group, e.g. maleimide group, or a fragment containing the antigen linking part thereof is reacted with a thiol group-containing cytotoxic substance, e.g. low-molecular carcinostatic agent, and the unreacted functional groups reactive with thiol group in the resultant complex are treated with a thiol group-containing low-molecular compound, e.g. L-cysteine, and sealed to afford the aimed cytotoxic protein complex. Conventional problems in which the residual unreacted functional groups reactive with thiol group initiate unfavorable reaction in purification, preservation or the living bodies are removed by the above-mentioned method and the aimed complex having high safety can be obtained.
Cognitive difficulties are reported as lasting sequelae within post COVID-19 condition. However, the chronicity of these difficulties and related factors of fatigue, mood, and perceived health have yet to be fully determined. To address this, the current longitudinal study aimed to clarify the trends of cognitive test performance and cognitive domain impairment following COVID-19 onset, and whether hospitalization influences outcomes. 57 participants who reported subjective cognitive difficulties after confirmed COVID-19 infection were assessed at baseline (~6 months post COVID-19) and follow-up (~15 months later) visits. Assessments included measures across multiple cognitive domains and self-report questionnaires of fatigue, mood, and overall health. Analyses were conducted in three stages: at the test score level (raw and adjusted scores), at the cognitive domain level, and stratified by hospitalization status during infection. Results at the test-score level indicate that cognitive performance remains relatively stable across assessments at the group level, with no significant improvements in any adjusted test scores at follow-up. Cognitive domain analyses indicate significant reductions in attention and executive functioning impairment, while memory impairment is slower to resolve. On self-report measures, there was a significant improvement in overall health ratings at follow-up. Finally, those hospitalized during infection performed worse on timed cognitive measures across visits and accounted for a larger proportion of cases with short-term and working memory impairment at follow-up. Overall, our findings indicate that cognitive difficulties persist both at test score and cognitive domain levels in many cases of post COVID-19 condition, but evidence suggests some improvement in global measures of attention, executive functioning and overall self-rated health. Furthermore, an effect of hospitalization on cognitive symptoms post COVID-19 may be more discernible over time.
In Cycle 1, participants will receive 3 step-up doses and a target dose. The doses will be given on Cycle 1 Days 1, 2-4, 8, and 9-11. Subsequently the target dose will be administered on Day 1 of each 21-day cycle.
Disparities in data underlying clinical genomic interpretation is an acknowledged problem, but there is a paucity of data demonstrating it. The All of Us Research Program is collecting data including whole-genome sequences, health records, and surveys for at least a million participants with diverse ancestry and access to healthcare, representing one of the largest biomedical research repositories of its kind. Here, we examine pathogenic and likely pathogenic variants that were identified in the All of Us cohort. The European ancestry subgroup showed the highest overall rate of pathogenic variation, with 2.26% of participants having a pathogenic variant. Other ancestry groups had lower rates of pathogenic variation, including 1.62% for the African ancestry group and 1.32% in the Latino/Admixed American ancestry group. Pathogenic variants were most frequently observed in genes related to Breast/Ovarian Cancer or Hypercholesterolemia. Variant frequencies in many genes were consistent with the data from the public gnomAD database, with some notable exceptions resolved using gnomAD subsets. Differences in pathogenic variant frequency observed between ancestral groups generally indicate biases of ascertainment of knowledge about those variants, but some deviations may be indicative of differences in disease prevalence. This work will allow targeted precision medicine efforts at revealed disparities.
The invention relates to the technical field of foot bath powder, in particular to foot bath powder and a production device thereof. A foot bath powder comprises the following components in parts by weight: 40% of snow lotus herb, 20% of cinnamon, 13.3% of ginger root, 13.3% of pepper, 6.7% of mulberry twig and 6.7% of vine of multiflower knotweed. The foot bath powder production device comprises a processing tank and a circulating air duct. An isolation sieve is arranged in the processing tank. The separating screen divides the interior of the processing tank into an upper chamber and a lower chamber. Two ends of the circulating air duct are respectively communicated with an upper cavity and a lower cavity inside the processing tank. A fan is arranged in the circulating air duct. The processing tank is also provided with an air inlet pipe for introducing humid air, ozone and hot air. In the formula, the snow lotus herb and the cassia twig warm the kidney and strengthen yang, warm and dredge channels and collaterals, the ginger root and the hot pepper assist in dispelling cold, prevent and treat chilblain, return yang and dredge collaterals, and the mulberry twig and the vine of multiflower knotweed assist in dredging collaterals and joints and relieving pain. The functions of warming the kidney, supporting yang, expelling wind, eliminating dampness, dispelling cold, dredging collaterals, promoting blood circulation, relieving pain and preventing and treating foot chilblain are exerted together.
<P>PROBLEM TO BE SOLVED: To minutely clarify a mechanism for recognizing double-stranded DNA in a natural immune mechanism.  <P>SOLUTION: It is clarified that histone H2B has not only a role as nucleosome formation but also an important role for I type interferon production by recognizing foreign double-stranded DNA and activating an intracellular signal. The complex of extrachromosomal histone H2B and a double-stranded DNA is provided. The method for screening a regulator of a complex of extrachromosomal histone H2B and a double-stranded DNA is provided. The method for screening a regulator of an intracellular signaling by a complex of extrachromosomal histone H2B and a double-stranded DNA is provided.  <P>COPYRIGHT: (C)2011,JPO&INPIT
OBJECTIVE: Minimally invasive endoscopic endonasal multiport approaches create additional visualization angles to treat skull base pathologies. The sublabial contralateral transmaxillary (CTM) approach and superior eyelid lateral transorbital approach, frequently used nowadays, have been referred to as the "third port" when used alongside the endoscopic endonasal approach (EEA). The endoscopic precaruncular contralateral medial transorbital (cMTO) corridor, on the other hand, is an underrecognized but unique port that has been used to repair CSF rhinorrhea originating from the lateral sphenoid sinus recess. However, no anatomical feasibility studies or clinical experience exists to assess its benefits and demonstrate its potential role in multiport endoscopic access to the other contralateral skull base areas. In this study, the authors explored the application and potential utility of multiport EEA combined with the endoscopic cMTO approach (EEA/cMTO) to three target areas of the contralateral skull base: lateral recess of sphenoid sinus (LRSS), petrous apex (PA) and petroclival region, and retrocarotid clinoidocavernous space (CCS).
METHODS: Ten cadaveric specimens (20 sides) were dissected bilaterally under stereotactic navigation guidance to access contralateral LRSS via EEA/cMTO. The PA and petroclival region and retrocarotid CCS were exposed via EEA alone, EEA/cMTO, and EEA combined with the sublabial CTM approach (EEA/CTM). Qualitative and quantitative assessments, including working distance and visualization angle to the PA, were recorded. Clinical application of EEA/cMTO is demonstrated in a lateral sphenoid sinus CSF leak repair.
RESULTS: During the qualitative assessment, multiport EEA/cMTO provides superior visualization from a high vantage point and better instrument maneuverability than multiport EEA/CTM for the PA and retrocarotid CCS, while maintaining a similar lateral trajectory. The cMTO approach has significantly shorter working distances to all three target areas compared with the CTM approach and EEA. The mean distances to the LRSS, PA, and retrocarotid CCS were 50.69 ± 4.28 mm (p < 0.05), 67.11 ± 5.05 mm (p < 0.001), and 50.32 ± 3.6 mm (p < 0.001), respectively. The mean visualization angles to the PA obtained by multiport EEA/cMTO and EEA/CTM were 28.4° ± 3.27° and 24.42° ± 5.02° (p < 0.005), respectively.
CONCLUSIONS: Multiport EEA/cMTO to the contralateral LRSS offers the advantage of preserving the pterygopalatine fossa contents and the vidian nerve, which are frequently sacrificed during a transpterygoid approach. This approach also offers superior visualization and better instrument maneuverability compared with EEA/CTM for targeting the petroclival region and retrocarotid CCS.
Part A will be administered in two periods, separated by a washout. In Period 1, subjects will receive cyclosporine alone. In Period 2, subjects will receive cyclosporine in combination with telaprevir.
UNLABELLED: The MUC1-C protein is aberrantly expressed in adenocarcinomas of epithelial barrier tissues and contributes to their progression. Less is known about involvement of MUC1-C in the pathogenesis of squamous cell carcinomas (SCC). Here, we report that the MUC1 gene is upregulated in advanced head and neck SCCs (HNSCC). Studies of HNSCC cell lines demonstrate that the MUC1-C subunit regulates expression of (i) RIG-I and MDA5 pattern recognition receptors, (ii) STAT1 and IFN regulatory factors, and (iii) downstream IFN-stimulated genes. MUC1-C integrates chronic activation of the STAT1 inflammatory pathway with induction of the ∆Np63 and SOX2 genes that are aberrantly expressed in HNSCCs. In extending those dependencies, we demonstrate that MUC1-C is necessary for NOTCH3 expression, self-renewal capacity, and tumorigenicity. The findings that MUC1 associates with ∆Np63, SOX2 and NOTCH3 expression by single-cell RNA sequencing analysis further indicate that MUC1-C drives the HNSCC stem cell state and is a target for suppressing HNSCC progression.
SIGNIFICANCE: This work reports a previously unrecognized role for MUC1-C in driving STAT1-mediated chronic inflammation with the progression of HNSCC and identifies MUC1-C as a druggable target for advanced HNSCC treatment.
A method of applying, through spray on, extruded or flow-on application, a projectile resistant material. The method includes selecting an epoxy, selecting a fiber, selecting a ratio for combining the epoxy and the fiber, based on the ratio, combining the epoxy and the fiber to form a malleable projectile resistant type material, and applying the material. The projectile resistant material includes an epoxy and several fibers. The fibers are mixed within the epoxy based on a predetermined ratio. The predetermined ratio is for determining the projectile resistance of the material. The fibers are randomly disposed within the epoxy.
PURPOSE:To efficiently exhibit the activity of a metallic phthalocyanine compd. over a long period of time by combining the activity, for example, deodorizing effect, possessed by the metallic phthalocyanine compd. with a water absorptive resin. CONSTITUTION:The metallic phthalocyanine compd. acts effectively as the catalyst to decompose malodors in the presence of water. The sufficient activity is not obtainable therewith if the moisture content does not sufficient. The moisture considered to be necessary in order to maintain the activity is assured by the combination use with the water absorptive resin so that the activity of the metallic phthalocyanine compd. is maintained at a high level over a long period of time. The water absorptive resin is, therefore, any as far as the resin has adequate water absorptivity and water retention characteristics, but the resin which absorbs the water of 2 times its own weight is more preferable in order to more effectively exhibit the activity of the metallic phthalocyanine compd. The resin which absorbs the water of 5 to 1000 times its own weight is more particularly preferably.
PURPOSE: To obtain both a metal chelate-forming peptide, capable of readily and stably chelating a radioactive metal nuclide without requiring treatment such as heating and not recognizing a nonspecific accumulation in vivo distribution of the labeled substance of the radioactive nuclide, and its use, and to provide a method for producing the peptide. CONSTITUTION: This metal chelate-forming peptide has an amino acid sequence comprising three amino acid residues of X1-X2-Cys in the order from the N end side. A physiologically active substance is bonded to the peptide to give the desired complex. The peptide or the complex is coordinated with a radioactive metal nuclide to give the objective compound. A radioactive diagnostic and radioactive therapeutic agent contains the compound. X1 is an arbitrary amino acid residue except Cys residue, X2 is an arbitrary amino acid residue except Cys residue and Pro residue. Functional groups at the N end, the C end and side chains of the chelate forming peptide may be substituted with a protecting group, etc., and each amino acid residue may be D-isomer or L- isomer.